MEA Lymphedema Treatment Market - Industry Trends and Forecast to 2033

Description

List of Tables

Middle East and Africa lymphedema treatment market is expected to reach USD 15,432.53 thousand by 2030 from USD 10,003.92 thousand in 2022 growing at the CAGR of 5.8% in the forecast period of 2023 to 2030.The new market report contains data for the historic year 2021, the base year of calculation is 2022 and the forecast period is 2023 to 2030.

Market Segmentation:

Middle East and Africa Lymphedema Treatment Market, By Treatment Type (Compression Therapy, Surgery, Drug Therapy, Laser Therapy, and Others), Treatment (Primary Lymphedema and Secondary Lymphedema), Affected Area (Genital, Lower Extremity, Upper Extremity, and Others), Age Group (Adult and Geriatric), Route of Administration (Oral, Injectable, and Others), End User (Hospitals, Ambulatory Surgical Centres, Speciality Clinics, and Others), Distribution Channel (Direct tender, Pharmacy stores, and Others), Country (South Africa, Saudi Arabia, U.A.E., Kuwait, Israel, and Rest of Middle East and Africa) - Industry Trends and Forecast to 2030.

Overview of Middle East and Africa Lymphedema Treatment Market Dynamics

Driver
Rising number of lymphedema cases around the globe
Restrain
High costs of treatment
Opportunity
Partnership and agreement by market players

Market Players

Some of the key market players operating in the Middle East and Africa lymphedema treatment market are listed below:

PAUL HARTMANN AG
3M
Convatec Inc.
JUZO
SIGVARIS GROUP
Tactile Medical
BIOCOMPRESSION SYSTEMS
Lohmann & Rauscher GmbH & Co. KG
ThermoTek
Cardinal Health
Essity (BSN medical GmbH)
Smith+Nephew
HERANTIS PHARMA Plc

1 INTRODUCTION 17

1.1 OBJECTIVES OF THE STUDY 17
1.2 MARKET DEFINITION 17
1.3 OVERVIEW OF THE MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET 17
1.4 LIMITATIONS 19
1.5 MARKETS COVERED 19

2 MARKET SEGMENTATION 22

2.1 MARKETS COVERED 22
2.2 GEOGRAPHICAL SCOPE 23
2.3 YEARS CONSIDERED FOR THE STUDY 24
2.4 CURRENCY AND PRICING 24
2.5 DBMR TRIPOD DATA VALIDATION MODEL 25
2.6 MULTIVARIATE MODELLING 28
2.7 PRODUCT TYPE LIFELINE CURVE 28
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 29
2.9 DBMR MARKET POSITION GRID 30
2.10 MARKET END USER COVERAGE GRID 31
2.11 VENDOR SHARE ANALYSIS 32
2.12 SECONDARY SOURCES 33
2.13 ASSUMPTIONS 33

3 EXECUTIVE SUMMARY 34

4 PREMIUM INSIGHTS 38

4.1 PESTEL'S ANALYSIS 39
4.2 PORTER'S MODEL 40

5 PIPELINE ANALYSIS FOR MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET 41

6 EPIDEMIOLOGY 42

7 REGULATORY GUIDELINES FOR MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET 43

7.1 U.S. 43
7.2 EUROPE 44
7.3 INDIA 44
7.4 MEXICO 45
7.5 CANADA 45

8 MARKET OVERVIEW 47

8.1 DRIVERS 49
- 8.1.1 RISE IN THE NUMBER OF LYMPHEDEMA CASES MIDDLE EAST AND AFRICALY 49
- 8.1.2 INCREASE IN THE PREVALENCE OF CANCERS 49
- 8.1.3 INCREASING NUMBER OF HEALTHCARE FACILITIES 50
- 8.1.4 AVAILABILITY OF MULTIPLE THERAPIES FOR LYMPHEDEMA 50
8.2 RESTRAINTS 51
- 8.2.1 HIGH COST OF TREATMENT 51
- 8.2.2 LACK OF AWARENESS ABOUT THE DISEASE 52
8.3 OPPORTUNITIES 52
- 8.3.1 INCREASING DRUG APPROVALS 52
- 8.3.2 RISING PARTNERSHIPS AND AGREEMENTS BY MAJOR PLAYERS 53
8.4 CHALLENGES 53
- 8.4.1 NO PERMANENT CURE FOR LYMPHEDEMA 53
- 8.4.2 LIMITED REIMBURSEMENT SCENARIO 53

9 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE 55

9.1 OVERVIEW 56
9.2 COMPRESSION THERAPY 57
- 9.2.1 COMPRESSION PUMPS 58
- 9.2.2 COMPRESSION GARMENTS 58
  - 9.2.2.1 COMPRESSION STOCKINGS 58
  - 9.2.2.2 COMPRESSION SLEEVES 58
  - 9.2.2.3 OTHERS 59
- 9.2.3 COMPRESSION BANDAGES & WRAPS 59
- 9.2.4 OTHERS 59
  - 9.2.4.1 STATIC COMPRESSION THERAPY 59
  - 9.2.4.2 DYNAMIC COMPRESSION THERAPY 59
9.3 SURGERY 60
- 9.3.1 LYMPHOVENOUS TRANSPLANT 60
- 9.3.2 LYMPHATICOVENOUS ANASTOMOSIS 60
- 9.3.3 LIPOSUCTION 61
- 9.3.4 OTHERS 61
9.4 DRUG THERAPY 61
- 9.4.1 NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) 62
- 9.4.2 RETINOIDS 62
- 9.4.3 ANTIBIOTICS 62
- 9.4.4 OTHERS 62
9.5 LASER THERAPY 63
9.6 OTHERS 64

10 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET, BY TYPE 65

10.1 OVERVIEW 66
10.2 SECONDARY LYMPHEDEMA 67
10.3 PRIMARY LYMPHEDEMA 68
- 10.3.1 LYMPHEDEMA PRAECOX (MEIGE DISEASE) 68
- 10.3.2 CONGENITAL LYMPHEDEMA 69
- 10.3.3 LYMPHEDEMA TARDA 69

11 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA 70

11.1 OVERVIEW 71
11.2 LOWER EXTREMITY 72
11.3 UPPER EXTREMITY 73
11.4 GENITALIA 74

12 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP 75

12.1 OVERVIEW 76
12.2 ADULT 77
12.3 GERIATRIC 78
12.4 PEDIATRIC 78

13 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 79

13.1 OVERVIEW 80
13.2 ORAL 81
13.3 INJECTABLE 82
13.4 TOPICAL 83

14 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET, BY END USER 84

14.1 OVERVIEW 85
14.2 HOSPITAL 86
14.3 SPECIALTY CLINICS 87
14.4 AMBULATORY SURGICAL CENTERS 88
14.5 OTHERS 89

15 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL 90

15.1 OVERVIEW 91
15.2 PHARMACY STORES 92
15.3 DIRECT TENDER 93
15.4 OTHERS 94

16 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET, BY REGION 95

16.1 MIDDLE EAST AND AFRICA 96
- 16.1.1 SOUTH AFRICA 100
- 16.1.2 SAUDI ARABIA 104
- 16.1.3 EGYPT 108
- 16.1.4 U.A.E. 112
- 16.1.5 ISRAEL 115
- 16.1.6 KUWAIT 119
- 16.1.7 REST OF MIDDLE EAST AND AFRICA 123

17 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET, COMPANY LANDSCAPE 124

17.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA 124

18 COMPANY PROFILE 125

18.1 TACTILE MEDICAL 125
- 18.1.1 COMPANY SNAPSHOT 125
- 18.1.2 REVENUE ANALYSIS 125
- 18.1.3 COMPANY SHARE ANALYSIS 126
- 18.1.4 PRODUCT PORTFOLIO 126
- 18.1.5 RECENT DEVELOPMENT 126
18.2 ESSITY (BSN MEDICAL GMBH) 127
- 18.2.1 COMPANY SNAPSHOT 127
- 18.2.2 COMPANY SHARE ANALYSIS 127
- 18.2.3 PRODUCT PORTFOLIO 128
- 18.2.4 RECENT DEVELOPMENT 128
18.3 3M 129
- 18.3.1 COMPANY SNAPSHOT 129
- 18.3.2 REVENUE ANALYSIS 129
- 18.3.3 COMPANY SHARE ANALYSIS 130
- 18.3.4 PRODUCT PORTFOLIO 130
- 18.3.5 RECENT DEVELOPMENTS 130
18.4 CARDINAL HEALTH 131
- 18.4.1 COMPANY SNAPSHOT 131
- 18.4.2 REVENUE ANALYSIS 131
- 18.4.3 COMPANY SHARE ANALYSIS 132
- 18.4.4 PRODUCT PORTFOLIO 132
- 18.4.5 RECENT DEVELOPMENT 132
18.5 LOHMANN & RAUSCHER GMBH & CO. KG 133
- 18.5.1 COMPANY SNAPSHOT 133
- 18.5.2 COMPANY SHARE ANALYSIS 133
- 18.5.3 PRODUCT PORTFOLIO 134
- 18.5.4 RECENT DEVELOPMENT 134
18.6 AIROS MEDICAL, INC. 135
- 18.6.1 COMPANY SNAPSHOT 135
- 18.6.2 PRODUCT PORTFOLIO 135
- 18.6.3 RECENT DEVELOPMENT 135
18.7 AVET PHARMACEUTICALS INC. 136
- 18.7.1 COMPANY SNAPSHOT 136
- 18.7.2 PRODUCT PORTFOLIO 136
- 18.7.3 RECENT DEVELOPMENT 136
18.8 BIOCOMPRESSION SYSTEMS 137
- 18.8.1 COMPANY SNAPSHOT 137
- 18.8.2 PRODUCT PORTFOLIO 137
- 18.8.3 RECENT DEVELOPMENT 137
18.9 CONVATEC INC. 139
- 18.9.1 COMPANY SNAPSHOT 139
- 18.9.2 PRODUCT PORTFOLIO 139
- 18.9.3 RECENT DEVELOPMENT 139
18.10 HERANTIS PHARMA PLC 140
- 18.10.1 COMPANY SNAPSHOT 140
- 18.10.2 RECENT DEVELOPMENT 140
18.11 HUNTLEIGH HEALTHCARE LIMITED 141
- 18.11.1 COMPANY SNAPSHOT 141
- 18.11.2 PRODUCT PORTFOLIO 141
- 18.11.3 RECENT DEVELOPMENT 141
18.12 JUZO 142
- 18.12.1 COMPANY SNAPSHOT 142
- 18.12.2 PRODUCT PORTFOLIO 142
- 18.12.3 RECENT DEVELOPMENT 142
18.13 KOYA MEDICAL 143
- 18.13.1 COMPANY SNAPSHOT 143
- 18.13.2 PRODUCT PORTFOLIO 143
- 18.13.3 RECENT DEVELOPMENT 143
18.14 MEDI GMBH & CO. KG 144
- 18.14.1 COMPANY SNAPSHOT 144
- 18.14.2 PRODUCT PORTFOLIO 144
- 18.14.3 RECENT DEVELOPMENT 144
18.15 MEGO AFEK LTD 145
- 18.15.1 COMPANY SNAPSHOT 145
- 18.15.2 PRODUCT PORTFOLIO 145
- 18.15.3 RECENT DEVELOPMENT 145
18.16 PAUL HARTMANN AG 147
- 18.16.1 COMPANY SNAPSHOT 147
- 18.16.2 REVENUE ANALYSIS 147
- 18.16.3 PRODUCT PORTFOLIO 148
- 18.16.4 RECENT DEVELOPMENTS 148
18.17 SANYLEG SRL A SOCIO UNICO 149
- 18.17.1 COMPANY SNAPSHOT 149
- 18.17.2 PRODUCT PORTFOLIO 149
- 18.17.3 RECENT DEVELOPMENT 149
18.18 SIGVARIS GROUP 150
- 18.18.1 COMPANY SNAPSHOT 150
- 18.18.2 PRODUCT PORTFOLIO 150
- 18.18.3 RECENT DEVELOPMENTS 151
18.19 SMITH +NEPHEW 152
- 18.19.1 COMPANY SNAPSHOT 152
- 18.19.2 REVENUE ANALYSIS 152
- 18.19.3 PRODUCT PORTFOLIO 153
- 18.19.4 RECENT DEVELOPMENT 153
18.20 THERMOTEK 154
- 18.20.1 COMPANY SNAPSHOT 154
- 18.20.2 PRODUCT PORTFOLIO 154
- 18.20.3 RECENT DEVELOPMENT 154

19 QUESTIONNAIRE 155

20 RELATED REPORTS 159

LIST OF TABLES

TABLE 1 PIPELINE ANALYSIS FOR LYMPHEDEMA TREATMENT: 41
TABLE 2 AN ANNUAL SURVEY OF HOSPITALS IN THE U.S., PUBLISHED IN 2021 50
TABLE 3 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 57
TABLE 4 MIDDLE EAST AND AFRICA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY REGION 2021-2030 (USD THOUSAND) 57
TABLE 5 MIDDLE EAST AND AFRICA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 58
TABLE 6 MIDDLE EAST AND AFRICA COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 58
TABLE 7 MIDDLE EAST AND AFRICA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2021-2030 (USD THOUSAND) 59
TABLE 8 MIDDLE EAST AND AFRICA SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 60
TABLE 9 MIDDLE EAST AND AFRICA SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 60
TABLE 10 MIDDLE EAST AND AFRICA DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 62
TABLE 11 MIDDLE EAST AND AFRICA DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 62
TABLE 12 MIDDLE EAST AND AFRICA LASER THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 63
TABLE 13 MIDDLE EAST AND AFRICA OTHERS IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 64
TABLE 14 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 67
TABLE 15 MIDDLE EAST AND AFRICA SECONDARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 67
TABLE 16 MIDDLE EAST AND AFRICA PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 68
TABLE 17 MIDDLE EAST AND AFRICA PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 68
TABLE 18 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2021-2030 (USD THOUSAND) 72
TABLE 19 MIDDLE EAST AND AFRICA LOWER EXTREMITY IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 72
TABLE 20 MIDDLE EAST AND AFRICA UPPER EXTREMITY IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 73
TABLE 21 MIDDLE EAST AND AFRICA GENITALIA IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 74
TABLE 22 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 77
TABLE 23 MIDDLE EAST AND AFRICA ADULT IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 77
TABLE 24 MIDDLE EAST AND AFRICA GERIATRIC IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 78
TABLE 25 MIDDLE EAST AND AFRICA PEDIATRIC IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 78
TABLE 26 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 81
TABLE 27 MIDDLE EAST AND AFRICA ORAL IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 81
TABLE 28 MIDDLE EAST AND AFRICA INJECTABLE IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 82
TABLE 29 MIDDLE EAST AND AFRICA TOPICAL IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 83
TABLE 30 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 86
TABLE 31 MIDDLE EAST AND AFRICA HOSPITAL IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 86
TABLE 32 MIDDLE EAST AND AFRICA SPECIALITY CLINICS IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 87
TABLE 33 MIDDLE EAST AND AFRICA AMBULATORY SURGICAL CENTERS IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 88
TABLE 34 MIDDLE EAST AND AFRICA OTHERS IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 89
TABLE 35 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 92
TABLE 36 MIDDLE EAST AND AFRICA PHARMACY STORES IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 92
TABLE 37 MIDDLE EAST AND AFRICA DIRECT TENDER IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 93
TABLE 38 MIDDLE EAST AND AFRICA OTHERS IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 94
TABLE 39 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND) 96
TABLE 40 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 96
TABLE 41 MIDDLE EAST AND AFRICA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 97
TABLE 42 MIDDLE EAST AND AFRICA COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 97
TABLE 43 MIDDLE EAST AND AFRICA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2021-2030 (USD THOUSAND) 97
TABLE 44 MIDDLE EAST AND AFRICA SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 97
TABLE 45 MIDDLE EAST AND AFRICA DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 98
TABLE 46 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 98
TABLE 47 MIDDLE EAST AND AFRICA PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 98
TABLE 48 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2021-2030 (USD THOUSAND) 98
TABLE 49 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 99
TABLE 50 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 99
TABLE 51 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 99
TABLE 52 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 99
TABLE 53 SOUTH AFRICA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 100
TABLE 54 SOUTH AFRICA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 100
TABLE 55 SOUTH AFRICA COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 100
TABLE 56 SOUTH AFRICA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2021-2030 (USD THOUSAND) 100
TABLE 57 SOUTH AFRICA SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 101
TABLE 58 SOUTH AFRICA DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 101
TABLE 59 SOUTH AFRICA LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 101
TABLE 60 SOUTH AFRICA PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 101
TABLE 61 SOUTH AFRICA LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2021-2030 (USD THOUSAND) 102
TABLE 62 SOUTH AFRICA LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 102
TABLE 63 SOUTH AFRICA LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 102
TABLE 64 SOUTH AFRICA LYMPHEDEMA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 102
TABLE 65 SOUTH AFRICA LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 103
TABLE 66 SAUDI ARABIA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 104
TABLE 67 SAUDI ARABIA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 104
TABLE 68 SAUDI ARABIA COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 104
TABLE 69 SAUDI ARABIA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2021-2030 (USD THOUSAND) 104
TABLE 70 SAUDI ARABIA SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 105
TABLE 71 SAUDI ARABIA DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 105
TABLE 72 SAUDI ARABIA LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 105
TABLE 73 SAUDI ARABIA PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 105
TABLE 74 SAUDI ARABIA LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2021-2030 (USD THOUSAND) 106
TABLE 75 SAUDI ARABIA LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 106
TABLE 76 SAUDI ARABIA LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 106
TABLE 77 SAUDI ARABIA LYMPHEDEMA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 106
TABLE 78 SAUDI ARABIA LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 107
TABLE 79 EGYPT LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 108
TABLE 80 EGYPT COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 108
TABLE 81 EGYPT COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 108
TABLE 82 EGYPT COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2021-2030 (USD THOUSAND) 108
TABLE 83 EGYPT SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 109
TABLE 84 EGYPT DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 109
TABLE 85 EGYPT LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 109
TABLE 86 EGYPT PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 109
TABLE 87 EGYPT LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2021-2030 (USD THOUSAND) 110
TABLE 88 EGYPT LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 110
TABLE 89 EGYPT LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 110
TABLE 90 EGYPT LYMPHEDEMA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 110
TABLE 91 EGYPT LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 111
TABLE 92 U.A.E. LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 112
TABLE 93 U.A.E. COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 112
TABLE 94 U.A.E. COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 112
TABLE 95 U.A.E. COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2021-2030 (USD THOUSAND) 112
TABLE 96 U.A.E. SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 113
TABLE 97 U.A.E. DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 113
TABLE 98 U.A.E. LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 113
TABLE 99 U.A.E. PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 113
TABLE 100 U.A.E. LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2021-2030 (USD THOUSAND) 114
TABLE 101 U.A.E. LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 114
TABLE 102 U.A.E. LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 114
TABLE 103 U.A.E. LYMPHEDEMA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 114
TABLE 104 U.A.E. LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 114
TABLE 105 ISRAEL LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 115
TABLE 106 ISRAEL COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 115
TABLE 107 ISRAEL COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 115
TABLE 108 ISRAEL COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2021-2030 (USD THOUSAND) 115
TABLE 109 ISRAEL SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 116
TABLE 110 ISRAEL DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 116
TABLE 111 ISRAEL LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 116
TABLE 112 ISRAEL PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 116
TABLE 113 ISRAEL LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2021-2030 (USD THOUSAND) 117
TABLE 114 ISRAEL LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 117
TABLE 115 ISRAEL LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 117
TABLE 116 ISRAEL LYMPHEDEMA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 117
TABLE 117 ISRAEL LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 118
TABLE 118 KUWAIT LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 119
TABLE 119 KUWAIT COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 119
TABLE 120 KUWAIT COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 119
TABLE 121 KUWAIT COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2021-2030 (USD THOUSAND) 119
TABLE 122 KUWAIT SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 120
TABLE 123 KUWAIT DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 120
TABLE 124 KUWAIT LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 120
TABLE 125 KUWAIT PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 120
TABLE 126 KUWAIT LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2021-2030 (USD THOUSAND) 121
TABLE 127 KUWAIT LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 121
TABLE 128 KUWAIT LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 121
TABLE 129 KUWAIT LYMPHEDEMA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 121
TABLE 130 KUWAIT LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 122
TABLE 131 REST OF MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 123

LIST OF FIGURES

FIGURE 1 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET: SEGMENTATION 22
FIGURE 2 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET: DATA TRIANGULATION 25
FIGURE 3 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET: DROC ANALYSIS 26
FIGURE 4 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET: MIDDLE EAST AND AFRICA VS REGIONAL ANALYSIS 27
FIGURE 5 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET: COMPANY RESEARCH ANALYSIS 27
FIGURE 6 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET: INTERVIEW DEMOGRAPHICS 29
FIGURE 7 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET: DBMR MARKET POSITION GRID 30
FIGURE 8 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET: MARKET END USER COVERAGE GRID 31
FIGURE 9 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET: VENDOR SHARE ANALYSIS 32
FIGURE 10 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET: SEGMENTATION 37
FIGURE 11 INCREASING PREVALENCE OF LYMPHEDEMA AND RISING HEALTHCARE EXPENDITURE ARE EXPECTED TO DRIVE THE GROWTH OF THE MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET IN THE FORECAST PERIOD OF 2023 TO 2030 38
FIGURE 12 THE COMPRESSION THERAPY SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET IN 2023 AND 2030 38
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET 48
FIGURE 14 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET: BY TREATMENT TYPE, 2022 56
FIGURE 15 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET: BY TYPE, 2022 66
FIGURE 16 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET: BY AFFECTED AREA, 2022 71
FIGURE 17 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET: BY AGE GROUP, 2022 76
FIGURE 18 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2022 80
FIGURE 19 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET: BY END USER, 2022 85
FIGURE 20 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2022 91
FIGURE 21 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET: COMPANY SHARE 2022 (%) 124